-+ 0.00%
-+ 0.00%
-+ 0.00%

JMP Securities Maintains Market Outperform on Prime Medicine, Lowers Price Target to $6

Benzinga·05/20/2025 13:26:17
Listen to the news
JMP Securities analyst Silvan Tuerkcan maintains Prime Medicine (NASDAQ:PRME) with a Market Outperform and lowers the price target from $10 to $6.